In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

被引：37

作者：

Jansen, W. T. A. ^{[1
]}

Verel, A. ^{[1
]}

Verhoef, J. ^{[1
]}

Milatovic, D. ^{[1
]}

机构：

[1] Univ Med Ctr, NL-3584 CX Utrecht, Netherlands

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 09期

关键词：

D O I：

10.1128/AAC.00100-07

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC50 and MIC90) were both 0.25 mu g/ml, irrespective of methicillin resistance. MIC50 and MIC90 were 0.25 and 0.5 mu g/ml for vancomycin-susceptible enterococci and 1 and 2 mu g/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by <= 0.12 mu g/ml.

引用

收藏

页码：3420 / 3424

页数：5

相关论文

共 11 条

[1]

Barrett John F, 2005, Curr Opin Investig Drugs, V6, P781

[2]

*CLIN LAB STAND I\, 2005, M100S15

[3] In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. [J].

Goldstein, EJC ;

Citron, DM ;

Merriam, CV ;

Warren, YA ;

Tyrrell, KL ;

Fernandez, HT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2149-2152

[4] Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus [J].

Higgins, DL ;

Chang, R ;

Debabov, DV ;

Leung, J ;

Wu, T ;

Krause, KA ;

Sandvik, E ;

Hubbard, JM ;

Kaniga, K ;

Schmidt, DE ;

Gao, QF ;

Cass, RT ;

Karr, DE ;

Benton, BM ;

Humphrey, PP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1127-1134

[5] Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria [J].

King, A ;

Phillips, I ;

Kaniga, K .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) :797-803

[6] Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus [J].

Leuthner, Kimberly D. ;

Cheung, Chrissy M. ;

Rybak, Michael J. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) :338-343

[7] In vitro activity of TD-6424 against Staphylococcus aureus [J].

Pace, JL ;

Krause, K ;

Johnston, D ;

Debabov, D ;

Wu, T ;

Farrington, L ;

Lane, C ;

Higgins, DL ;

Christensen, B ;

Judice, JK ;

Kaniga, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3602-3604

[8] Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects [J].

Shaw, JP ;

Seroogy, J ;

Kaniga, K ;

Higgins, DL ;

Kitt, M ;

Barriere, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :195-201

[9] Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria [J].

Stryjewski, ME ;

O'Riordan, WD ;

Lau, WK ;

Pien, FD ;

Dunbar, LM ;

Vallee, M ;

Fowler, VG ;

Chu, VH ;

Spencer, E ;

Barriere, SL ;

Kitt, MM ;

Cabell, CH ;

Corey, GR .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) :1601-1607

[10] Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria:: FAST 2 study [J].

Stryjewski, ME ;

Chu, VH ;

O'Riordan, WD ;

Warren, BL ;

Dunbar, LM ;

Young, DA ;

Vallée, M ;

Fowler, VG ;

Morganroth, J ;

Barriere, SL ;

Kitt, MM ;

Corey, GR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :862-867